# Prevention of cardiovascular disease in current and former employees of the Ford motor company, Germany

Submission date	Recruitment status No longer recruiting	<ul><li>Prospectively registered</li></ul>		
26/05/2011		Protocol		
Registration date	Overall study status	Statistical analysis plan		
28/07/2011	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
14/03/2023	Circulatory System			

## Plain English summary of protocol

Background and study aims

Cardiovascular diseases (CVD), including heart disease, heart attack and stroke, are a major cause of suffering and disability in many patients. Therefore, there is an urgent need for treatment strategies to prevent CVD, especially in healthy individuals at high risk for CVD. Decades of research have shown that CVD results from multiple risk factors, including smoking, high blood cholesterol, high blood pressure, obesity, chronic stress and depression. Treatment strategies for single risk factors are available, but, until now, only very few studies have targeted all of the aforementioned risk factors at the same time in a larger sample of healthy individuals at high risk for CVD. This study aims to fill this gap. The aim of this study is to find out whether the PreFord intervention reduces the risk of CVD.

## Who can participate?

Adults with no evidence of existing CVD, but at high risk for CVD in the future

## What does the study involve?

Participants are randomly allocated to either the PreFord intervention or routine care by their GPs. The PreFord intervention consists of 75 hours (total), divided into 30 sessions (2.5 hours each), two times a week, over a period of 15 weeks. It includes health education (e.g., the heart and vessels, healthy food, heart medication, etc), exercise, a smoking cessation programme if necessary, and LifeSkills, an approach to enhance stress resilience and social relationships at work and leisure time. The intervention is accompanied by a guideline-based drug treatment for high blood cholesterol and high blood pressure, if necessary. Well being, health behaviour and CVD risk factors are assessed before and after the intervention, and annually for 5 years. The intervention and each follow-up assessment are free of charge, and participants are free to join or leave the study whenever they wish.

What are the possible benefits and risks of participating? Not provided at time of registration Where is the study run from?
German Sports University Cologne

When is the study starting and how long is it expected to run for? August 2004 to July 2013

Who is funding the study?
Bayer Vital (Germany), Pronova BKK (Germany) and AstraZeneca (Germany)

Who is the main contact? Prof. Hans-Georg Predel predel@dshs-koeln.de

## Contact information

## Type(s)

Scientific

#### Contact name

Prof Hans-Georg Predel

#### Contact details

German Sports University Cologne Cologne (Koeln) Germany 50931

predel@dshs-koeln.de

## Additional identifiers

**Protocol serial number** N/A

# Study information

#### Scientific Title

Multimodal intervention for primary prevention of cardiovascular disease in current and former employees of the Ford motor company, Germany - the PreFord trial

#### Acronym

PreFord

## Study objectives

A multimodal intervention for primary prevention of cardiovascular disease (CVD) will reduce multiple biological and psychosocial cardiac risk factors and cardiac events.

Re-evaluation of cardiovascular risk and cardiac events annually up to 5 years.

## Ethics approval required

## Old ethics approval format

## Ethics approval(s)

- 1. North Rhine Medical Association (Aerztekammer North Rhine) Ethics Committee, 20/12/2004, ref: 2004079
- 2. Faculty of Medicine Ethics Committee, University of Cologne, 02/02/2004, ref: 03-217

## Study design

Two-armed randomized controlled clinical trial

## Primary study design

Interventional

## Study type(s)

Prevention

## Health condition(s) or problem(s) studied

Prevention of cardiovascular disease

#### **Interventions**

Multimodal intervention for outpatients, two sessions a week in the afternoon for three months (75 hours total):

- 1. Health education
- 2. Exercise therapy
- 3. Smoking cessation programme
- 4. Stress management (LifeSkills)

## Intervention Type

Other

#### Phase

Not Applicable

## Primary outcome(s)

European Society of Cardiology risk score

## Key secondary outcome(s))

- 1. Health behaviour (physical fitness, smoking, BMI)
- 2. CVD risk factors, e.g. low-density-lipoprotein cholesterol (LDL-C), total cholesterol, trigycerides, blood pressure, diabetes mellitus, depression and anxiety (HADS), Type-D pattern (DS-14)

## Completion date

31/07/2013

# **Eligibility**

## Key inclusion criteria

1. Adult men and women with no evidence for CVD and elevated risk according to the (European Society of Cardiology) ESC risk score > 5%

2. Informed consent

## Participant type(s)

**Patient** 

## Healthy volunteers allowed

No

## Age group

Adult

#### Sex

All

## Total final enrolment

447

## Key exclusion criteria

Severe somatic or psychiatric morbidity, e.g. malignancies, psychosis, drug addiction

#### Date of first enrolment

01/08/2004

## Date of final enrolment

31/07/2013

## Locations

## Countries of recruitment

Germany

## Study participating centre German Sports University Cologne Cologne (Koeln)

Cologne (Koeln Germany 50931

# Sponsor information

## Organisation

German Sports University (Germany)

## **ROR**

https://ror.org/0189raq88

# Funder(s)

## Funder type

Industry

#### Funder Name

Bayer Vital (Germany)

## Funder Name

Pronova BKK (Germany)

## Funder Name

AstraZeneca (Germany)

# **Results and Publications**

## Individual participant data (IPD) sharing plan

Not provided at time of registration

## IPD sharing plan summary

Not provided at time of registration

## **Study outputs**

Output type	Details	Date created Date ac	lded Peer reviewed	? Patient-facing?
Results article	results	01/02/2004	Yes	No
Results article	results	01/02/2012	Yes	No
Results article	results	01/09/2017	Yes	No
Other publications	Secondary analysis	23/02/2023 14/03/2	2023 Yes	No
Participant information sheet	Participant information sheet	11/11/2025 11/11/2	2025 No	Yes